contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


oriola-softer-profitability-good-growth-evli

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

Oriola is a pharmaceutical group with a particular focus on the distribution of pharmaceuticals to other players in the industry. The company offers services to pharmacies and other pharmaceutical companies, which includes, for example, negotiations with suppliers and distribution of products. The largest operations are in the Nordic and Baltic regions. The headquarters are located in Espoo.

There have been changes in the ownership of the Swedish pharmacy company half-owned by Oriola. The Lithuanian owner of the other half has sold its stake in the Swedish pharmacy company from the Euroapotheca Group, which operated pharmacy activities, to another group company. Euroapotheca retained the Baltic pharmacy operations, and the ownership of the Swedish pharmacy company it held has been transferred to a Dutch holding company of the Lithuanian group’s parent company. Following these arrangements, this holding company also includes the Lithuanian group parent company’s grocery store businesses in Poland and Bulgaria. From a business perspective, the ownership of the half of the Swedish pharmacy company is now in a rather unusual holding company. https://www.euroapotheca.lt/#euroapotheca-sold-shares-in-the-company-holding-a-pharmacy-chain-in-sweden-to-a-related-company From Oriola’s perspective, the interesting part of the matter is the price at which the half-ownership of the Swedish pharmacy company was sold. Based on the companies’ financial statements and announcements, the price for the half-stake in the Swedish pharmacy company in the transaction was approximately 200 million euros, which is at the same level as the value of the half-share of the pharmacy company on Oriola’s balance sheet. Everyone can evaluate in their own silos whether the Lithuanian group’s internal transaction was made at fair value. In this case, the fair value of the purchase price, 200 million euros, is supported by the fact that when determining the purchase price, factors such as financiers’ assessments and the requirements of both the Lithuanian and Dutch tax authorities had to be taken into account. Selling assets at a potential overprice from Lithuania to the Netherlands, thereby realizing potential future losses in a Dutch holding company, would also be an unusual operating model. On these grounds, it can be reasonably estimated that the fair value of Oriola’s ownership stake in the Swedish pharmacy company would also be 200 million euros.

Here are Evli’s thoughts on Oriola.   Oriola started off the year with a lower-than-expected improvement in adj. EBITDA due to performance of the advisory business and elevated group costs, but we expect performance to pick up during the year.   ACCUMULATE with a target price of EUR 1.0 With our estimates fairly intact, we retain our target price of EUR 1.0 and ACCUMULATE-rating. Our SOTP-model equity value is down to EUR 1.31 (1.54), mostly due to net debt, affected by timing of changes in working capital.                    Inderes              Oriola: Soft start but expecting improvement - Evli - Inderes    Oriola started of the year with a lower-than-expected improvement in adj. EBITDA due to performance of the advisory business and elevated group costs, but we expect performance to pick up during...

Rauli has written a new company report on Oriola following the Q1 results  Oriola’s Q1 result improved from the comparison period but fell short of our estimates. The company reiterated its positive full-year guidance, but our estimate decreased especially regarding the joint venture Kronans. We see value in the company, but also significant risks for the coming years. We reiterate our Accumulate recommendation and EUR 1.1 target price.                   Inderes              Oriola Q1'26: Hidas nousutrendi jatkui - Inderes    Yhtiö toisti koko vuoden positiivisen ohjeistuksen, mutta ennusteemme laski etenkin yhteisyritys Kronansin osalta.

Rauli interviewed Oriola’s CEO Katarina Gabrielson after the Q1 release                    Inderes              Oriola Q1'26: Uudet taloudelliset tavoitteet (eng.) - Inderes    Aika: 29.04.2026 klo 13.21 Vakaan vuoden aloituksen lisäksi Oriola kertoi tulospäivänä uudesta raportointirakenteesta ja uusista taloudellisista tavoitteista.                             Topics: 00:00 Introduction  00:09 New reporting structure  02:38 Q1 highlights  03:19 Declining results in the services segment  03:57 Weakness in advisory services  04:22 Kronans Apotek  04:53 Middle East crisis and energy prices  05:35 Guidance and outlook  06:28 New financial targets

Here are Rauli’s quick comments on Oriola’s Q1 result.  Oriola’s adj. EBITDA improved from the comparison period but fell short of our expectations. The result of the associate company Kronans continued to be loss-making and was also weaker than our expectations. As expected, the company reiterated its guidance for an improving full-year adj. EBITDA. The company also announced new financial targets, which will be presented in two weeks at the Capital Markets Day. The result puts slight downward pressure on our forecasts.                   Inderes – 29 Apr 26              Oriola Q1’26 -pikakommentti: Tulos jäi odotuksista, myös uudet tavoitteet...    Oriolan oik. käyttökate parani vertailukaudesta, mutta jäi odotuksistamme. Yhtiö toisti ohjeistuksensa koko vuoden paranevasta oik. käyttökatteesta odotetusti.

Inderes              Oriola Oyj:n osavuosikatsaus tammi-maaliskuulta 2026 - Inderes    Oriola Oyj:n pörssitiedote 29.4.2026 klo 8.30Oriola Oyj:n osavuosikatsaus tammi-maaliskuulta 2026Ensimmäisen vuosineljänneksen tulos odotusten mukainenTammi-maaliskuun 2026 pääkohdat Laskutus...                              The loss includes Oriola’s share of the joint venture Kronans Apotek’s result -2.3 (-1.0) million euros.    What can one even say to this anymore. It’s soft. At the beginning of the year, it was announced that the dividend would practically be halved, and with this performance, it’s possible that no dividend will be paid at all next year. The full-year guidance was reiterated, but when performance is at this level, we can expect a negative profit warning (negari) later this year. On top of this, there’s the uncertain ERP project, a new distribution center, and the challenges in Sweden. The current CEO has been in their position for 4 years and hopefully won’t continue much longer. If the CMD is bungled and the share price dips, for example, due to some financing arrangement, the CEO should be shown the door immediately. This performance just isn’t enough. The CEO’s only task has been to turn Kronans’ profitability positive, and they have failed completely in this. Compared to peers, the unprofitability of operations is incomprehensible. The CEO is also the Chairman of the Board of Kronans alongside their own post, so the tools for change have been available, but the performance has been abysmally poor.

I agree with this and have been wondering about that practice. All sorts of other strange things have been done in the company over the years; this would be a good basis for an activist investor.

Oriola

Oriola posted fairly decent figures in Q1. Net sales and invoicing growth continued at a good pace, with the latter up 8.1% y/y. The adj. EBITDA of EUR 7.7m fell well short of our EUR 8.5m expectation...

Oriola posted fairly decent figures in Q1. Net sales and invoicing growth continued at a good pace, with the latter up 8.1% y/y. The adj. EBITDA of EUR 7.7m fell well short of our EUR 8.5m expectations, with profitability in the Services-segment declining y/y.